Topics

TOPICS

ANEMIA

Interleukin-1β Inhibition Linked to Reduced Incidence of Anemia

Bleeding Incidences in Patients With Sickle Cell Disease

BLEEDING DISORDERS

Caution Urged for Genetic Screening in Children Suspected of Having Inherited Bleeding Disorders

Age May Affect Factor VIII Levels in Nonsevere Hemophilia A

GENERAL HEMATOLOGY

FDA Allows Use of COVID-19 Convalescent Plasma for Severely Ill Patients Under Emergency IND

IDSA Issues Recommendations for COVID-19 Testing

LEUKEMIA

Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy

Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes

LYMPHOMA

Lymphoid Malignancies: Novel Transplantations Are Improving Outcomes

Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine

MYELODYSPLASTIC SYNDROMES

Iron Chelation Therapy Treats Iron Overload in MDS

Reduced Transfusion Burden With Luspatercept in Anemia From Lower-Risk Myelodysplastic Syndromes

MYELOMA

Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Multiple Myeloma

FDA Approves New Treatment Option for Multiple Myeloma

SIDE EFFECT MANAGEMENT

Opioid Therapy for Cancer Pain May Be Associated With High Risk for Aberrant Opioid Use

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

THALASSEMIAS

Managing Complications Associated With Increased Longevity in Beta Thalassemia

Novel Conditioning Regimen for Haploidentical HSCT in Severe Thalassemia

THROMBOTIC DISORDERS

Integrin Alpha 9 May Modulate Arterial Thrombosis

Deep Vein Thrombosis Incidence and Pulmonary Embolism Risk Stratification

Next post in Lymphoma

CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy.

Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine